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Brainstem gliomas are not nearly as common in adults as they are in children. They are 
likely the final common consequence not of a single disease process but of several. They 
can be difficult to diagnose, and are challenging to treat. Clinical studies of this diagnosis 
are few and generally small. Because of these factors, our understanding of the biology 
of adult brainstem glioma is incomplete. However, the knowledge base is growing and 
progress is being made. In this article, we review the current state of knowledge for 
brainstem glioma in adults and identify key areas for which additional information is 
required.
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inTRODUCTiOn
The past several years have yielded important insights into the biology of glioma in adults. Efforts 
such as The Cancer Genome Atlas (TCGA) have comprehensively cataloged the litany of somatic 
alterations occurring in glioblastoma and lower grade gliomas, leading to discoveries such as the 
importance of IDH1 mutations in the development of a low-grade glioma and secondary glioblastoma 
(1). Pediatric diffuse intrinsic pontine glioma (DIPG) – the most frequent malignant primary brain 
tumor of childhood – on the other hand, has been found to have substantially different biological 
underpinnings. Eighty percent of these tumors, for example, contain mutations in genes that encode 
histone H3 (2).
At the nexus of these two diagnoses is brainstem glioma in adults. Unfortunately, it is perhaps 
more apt to describe adult brainstem glioma as the valley shrouded in shadow between the two 
growing mountains of knowledge that represent adult glioma and pediatric DIPG, as few studies 
have investigated this particular diagnosis. The anatomical basis of adult brainstem glioma does not 
lend itself to easy study, as the brainstem is packed full of brainstem nuclei and white matter tracts 
that are essential for basic functions. Resection is often not possible; even biopsies are challenging 
with significant risk for complications.
Within the umbrella of adult brainstem glioma, there is a subset of tumors that is similar in 
appearance and potentially similar in etiology to childhood DIPG, but with slightly older onset, 
generally affecting young adults. There is another subset of more well-circumscribed lesions that 
shares clinical and radiographic features with pilocytic astrocytoma, also with a younger median 
age at onset. The subset of adult brainstem gliomas presenting in later adulthood are typically more 
akin to other de novo malignant gliomas of adulthood. Yet despite these differences, there are also 
commonalities between these entities in terms of clinical considerations.
In this article, we will review the current state of knowledge (and lack of knowledge) for adult 
brainstem glioma and highlight prospects for advances in therapy.
FiGURe 1 | Brain MRi showing presence of brainstem glioma in a 82-year-old-woman with histological diagnosed astrocytoma, grade iii. (A) Axial, 
post-gadolinium MRI sequences showing a cystic, enhancing left pontine mass. (B) Axial, FLAIR MRI sequences showing surrounding edema in the left pontine 
mass.
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CLiniCAL FeATUReS
Appearance and Presentation
In contrast to pediatric DIPG, which accounts for approximately 
20% of pediatric primary brain neoplasms, adult brainstem 
glioma constitutes less than 2% of adult gliomas, with a slight 
male preponderance (3, 4). Median age at diagnosis is in the mid-
30s, though brainstem gliomas can present in any decade of life.
As befits a diagnosis that encompasses an array of pathophysi-
ologic alterations, the radiographic appearance of adult brainstem 
glioma varies widely, with approximately 40% demonstrating 
enhancement (3, 5). By comparison, in pediatric DIPG, con-
trast enhancement is usually not a prominent feature. Contrast 
enhancement itself can take on a variable appearance, with some 
tumors exhibiting minimal or partial enhancement, and others 
showing robust enhancement. MR spectroscopy can be a useful 
aid for diagnosis, as elevation of the choline/NAA ratio is often 
detectable, with one analysis of adult brainstem gliomas showing 
this finding in 100% of cases analyzed (3). FDG–PET may also be 
helpful in differentiating aggressive lesions from indolent ones (6).
Brainstem gliomas are centered in the pons in approximately 
60% of cases, but can also arise from the midbrain or medulla, and 
can infiltrate beyond the brainstem (7). They can be exophytic or 
expansile on imaging, or, as is the case with classic DIPG, can be 
infiltrative and diffuse with little notable mass effect (Figure 1).
Clinically, it is important to distinguish between gliomas 
that involve the midbrain tectum  –  which often behave indo-
lently – and classic diffuse pontine gliomas, which often do not 
enhance with contrast or have varying enhancement patterns. 
Tectal gliomas are typically low-grade, non-enhancing, and 
often non-progressive. They are diagnosed most frequently in 
childhood, but can be detected at any age. Observation is often 
a reasonable management option, and when intervention is 
warranted, often it is only to address obstructive hydrocephalus. 
A small subset of tectal glioma may behave more aggressively; 
contrast enhancement and the development of cystic changes 
may herald such progression (8). Because of their distinct natural 
history, tectal gliomas are generally not considered in the same 
vein as other brainstem gliomas, and will not be further addressed 
in this review.
Histologically, adult brainstem gliomas can have an astrocytic, 
oligodendroglial, or mixed appearance, with astrocytic tumors 
further characterized as either pilocytic or diffusely infiltrative. 
A  single-institution Italian retrospective analysis of 21 patients 
with histologically confirmed disease identified 2 pilocytic astro-
cytomas, 9 low-grade astrocytomas, 8 anaplastic astrocytomas, 
and 1 glioblastoma (3). An MD Anderson retrospective analysis 
that included 98 cases with histology identified 28 glioblastomas, 
43 anaplastic astrocytomas, 15 diffuse astrocytomas, and 11 
gliomas not otherwise specified (5).
The most frequent presenting symptom for adult brainstem 
glioma is headache, which can be a manifestation of hydrocepha-
lus. Cranial nerve deficits and long tract signs are also common. 
“Crossed” deficits, in which facial signs and symptoms are 
contralateral from arm/leg signs and symptom, are another char-
acteristic hallmark of brainstem pathology. Occasionally, clinical 
decline can precede radiographic progression, as the density of 
critical structures in the brainstem leaves little margin for growth 
before deficits occur.
Prognostic Considerations
Whereas pediatric DIPG is associated with a dismal prognosis of 
10 months, with only 10% of pediatric patients living >2 years 
beyond diagnosis, median survival for adult brainstem glioma is 
in the grim-but-not-quite-as-dismal range of 30–40 months (5). 
Furthermore, because adult brainstem gliomas vary widely in 
their aggressiveness, prognosticating outcome for an individual 
patient at diagnosis can be difficult.
Increasing tumor grade and contrast enhancement are 
associated with significantly reduced survival. An analysis of 17 
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adults with DIPG demonstrated a median OS of 57 months for 
low-grade vs. 16  months for high-grade gliomas (9). Contrast 
enhancement correlated strongly with histological grade in 
this study – median OS in patients with non-enhancing DIPG 
was 57 vs. 13 months for patients with enhancing tumors. The 
MD Anderson retrospective analysis of adult brainstem glioma 
patients demonstrated a median OS of 77.0  months for WHO 
grade 2 diffuse astrocytoma, 21.1  months for WHO grade 3 
anaplastic astrocytoma, and 14.8 months for glioblastoma (5).
Increasing age is also associated with worsened survival. The 
MD Anderson retrospective study demonstrated median survival 
of 34 months for patients 22–59 years of age, but only 14.2 months 
for patients 60 and over (5).
Other characteristics that have been identified as favorable 
prognostic factors include duration of symptoms >3 months, and 
the presence of “necrosis” on MRI (9, 10). Location also factors 
into prognosis – the MD Anderson study demonstrated a median 
survival of 66.0  months for midbrain tumors, 25.3  months for 
pontine tumors, and 51.3  months for medullary tumors (5). 
Predisposing factors are not well-defined, though there is one 
case report of a brainstem glioma developing 8 years after radia-
tion treatment for a pituitary adenoma (11).
Treatment Options
For pediatric DIPG, standard of care treatment consists of 
involved field radiation therapy, typically to a dose of approxi-
mately 54–60 Gy. Alternative fractionation schemes for pediatric 
DIPG – including hyperfractionated, accelerated, and hypofrac-
tionated regimens – do not improve survival, with significantly 
increased risks of radiation toxicity at doses >64 Gy (12).
To date, pediatric treatment trials for DIPG have failed to 
identify a significant benefit with chemotherapy. A phase 2 trial 
of the oral alkylating drug temozolomide along with radiation 
followed by adjuvant temozolomide  –  similar to the standard 
Stupp regimen for adult malignant glioma – resulted in median 
OS of only 9.5 months (13).
Other failed strategies in the pediatric DIPG population 
include high-dose chemotherapy, and metronomic approaches 
with etoposide, trophosphamide, or temozolomide (14–16). 
Several phase I and phase II trials of targeted therapy have 
been conducted, including trials of anti-EGFR drugs such as 
erlotinib, gefitinib, and nimotuzumab; trials targeting PDGFR 
using imatinib; trials utilizing the farnesyltransferase inhibitors 
tipifarnib and lonafarnib; trials of antiangiogenic drugs such as 
bevacizumab, semaxanib and the integrin inhibitor cilengitide; a 
trial of the mTOR inhibitor everolimus; and a trial of the multi-
kinase inhibitor vandetanib (17–27). Overall, the results of these 
trials have been unimpressive, though long-term disease control 
has been reported in a small subset of these patients.
For adults with brainstem glioma, involved field radiation 
therapy, typically to a dose of 54–60 Gy, is considered standard 
upfront therapy, as is the case with pediatric DIPG. Few stud-
ies utilizing chemotherapy for the treatment of adult brainstem 
glioma have been performed, and the ones that have are often 
limited to single-arm, single-institution, or retrospective 
analyses. However, there is reason to hope that chemotherapeutic 
treatment for adults is more fruitful. The final results of RTOG 
9802 demonstrate a clear benefit for combined chemoradiation 
vs. radiation therapy alone for patients with so-called “high-risk” 
grade 2 glioma, defined in this study as patients older than 40 or 
who had undergone subtotal resection. The benefits of combined 
treatment were particularly striking in patients with tumors 
that harbor an IDH1 mutation. Although the recently published 
results do not delineate how many of the 251 patients enrolled 
on this study had brainstem disease, the study adds to the body 
of evidence supporting a combined treatment approach for adult 
glioma patients of any age.
Perhaps the best line of evidence supporting the use of upfront 
chemotherapy (along with radiation) for adult brainstem glioma 
comes from the MD Anderson retrospective analysis, which 
demonstrated a striking difference in survival in adults with 
brainstem glioblastoma treated with the standard Stupp regimen 
(concurrent radiation and temozolomide followed by adjuvant 
temozolomide) vs. those who were not – median OS for patients 
treated with the Stupp regimen was 23.1 vs. 4.0  months for 
patients who were not (5). Of course, the scope of this analysis 
is limited by its small numbers (28 patients) and retrospective 
nature, as patients treated with the Stupp regimen tended to 
have better performance status at baseline (KPS 90 vs. 80), and 
were treated in the temozolomide era in which other advances 
in treatment and management may influence survival. A single-
institution retrospective analysis of 15 adults with “low grade” 
diffuse brainstem glioma (defined either histologically or by 
radiographic appearance) treated with temozolomide at recur-
rence demonstrated a median PFS of 9.5 months and median OS 
of 14.4 months (9). Clinical improvement was noted in 60% of 
patients, and radiographic responses occurred in 6 of 15 patients 
(4 partial and 2 minor responses).
Re-irradiation is another potential treatment strategy for 
recurrent adult brainstem gliomas. A single-institution retro-
spective analysis of five adults with progressive/recurrent brain-
stem glioma treated with a repeat course of radiation resulted 
in post-treatment survival ranging from 3 to 36+ months (28). 
Four of the five patients showed improvement in performance 
status post-treatment, with the other patient manifesting new 
symptoms potentially attributable to radiation toxicity.
The antiangiogenic drug bevacizumab may also have a role in 
the management of adults with brainstem glioma. A retrospec-
tive analysis that included 17 patients treated with bevacizumab 
at progression demonstrated median PFS of 2.0  months with 
6-month PFS of 21%, including one patient who was progres-
sion free for 9  months (5). While somewhat encouraging, the 
6-month PFS of 21% pales in comparison to the 40% 6-month 
PFS seen with supratentorial glioblastoma. It is also worth noting 
that bevacizumab may have a palliative benefit in addition to its 
anti-neoplastic activity. Bevacizumab reduces vasogenic cerebral 
edema, which frequently results in symptomatic improvement. 
Furthermore, this effect often allows patients to taper their steroid 
dose, which can have downstream benefits as well. Because beva-
cizumab both vasoconstricts and reduces vascular permeability, 
treatment with bevacizumab often mitigates contrast enhance-
ment. Monitoring for changes on T2/FLAIR and Diffusion-
Weight Imaging (DWI) takes on additional importance in this 
circumstance.
TABLe 1 | Summary of adult and pediatric brainstem gliomas.
Pediatric DiPG Adult brainstem glioma Adult supratentorial GBM
Incidence 20% of pediatric brain tumors 2% of adult glioma 80% of primary malignant brain tumors
Median age of onset 5–9 mid-30s 64
MRI contrast enhancement Usually nonenhancing Variable enhancement Strong enhancement 
Significant gene alterations HIST1H3B IDH1 MGMT promoter methylation
H3F3A (K27M) H3F3A (K27M) EGFR amplification





Standard initial treatment RT RT RT and temozolomide
Median overall survival 10 months 30–40 months (varies by grade) 12–18 months
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SCienTiFiC UnDeRSTAnDinG
Few scientific studies have specifically investigated brainstem 
glioma in adults, but our understanding of the biology of pedi-
atric DIPG has been greatly enhanced over the past few years by 
several landmark studies (Table 1). In one such study published 
in 2012, Wu et al. identified mutations in H3F3A and HIST1H3B 
in 78% of pediatric DIPG (2). The mutations in both of these 
genes result in a K27M amino acid substitution in histone H3, 
and suggest epigenetic dysregulation as an important contributor 
to the pathogenesis of pediatric DIPG. In contrast, histone H3 
mutations rarely occur in adult supratentorial glioblastoma (29).
Somatic IDH mutations, on the other hand, are very common 
in adult non-brainstem lower-grade (grade 2/3) gliomas. In the 
TCGA analysis of such tumors, 80.1% were found to harbor 
IDH mutations. These mutations were previously thought to be 
uncommon in adult brainstem glioma, as studies of pediatric 
DIPG did not identify any such mutations, and IDH1 R132H 
mutations as detected by immunohistochemistry were found 
in only 6% of the adult brainstem gliomas in one study (5). 
However, a whole-exome sequencing study of brainstem glioma 
demonstrated that IDH mutations are not altogether uncommon 
in the subset of tumors from adults, particularly when alternative 
non-R132H mutations (which constitute only 5% of IDH muta-
tions in adult supratentorial glioblastoma) are included (30). Of 
the 13 adult brainstem gliomas that underwent whole exome 
sequencing in this study, 5 (38%) were IDH1 mutated. There 
were three IDH1 R132H mutations, one R132C, and one R132L 
mutation. All of these cases also had mutant TP53, and four of the 
cases had mutant ATRX. Genetically, this group resembles classic 
IDH1 mutant cerebral astrocytomas, which also usually harbor 
mutations in TP53 and ATRX. Mean age of these 5 patients was 
40 and the predominant tumor location was in the pons, with 
all 5 having a pontine location, four of which were located both 
in the pons and medulla. Histopathology was oligoastrocytoma 
grade 2 or 3 in four cases and GBM in one. IDH1-mutant cases 
had a significantly better median survival than the IDH1 wild-
type cases.
In the same study, H3F3A mutations were identified in 7/13 
(54%) tumors. Each of these seven cases additionally harbored a 
mutation in either TP53 (four cases) or PPM1D (3 cases). PPM1D 
suppresses the activation of several DNA damage response 
mediators; the mutations identified in PPM1D enhanced this 
activity. One of these cases carried a mutation in PDGFRA (in 
addition to PPM1D). One had a mutation in NF1 (in addition to 
PPM1D). Mean age of these adult patients was 29, and the pre-
dominant location was in the medulla (four cases) and midbrain 
(2 cases). Two of the cases had dual location in the medulla and 
pons. Notably, while all the IDH1 mutant cases had a pontine 
location, only 2/7 of the H3F3A mutant cases had a pontine 
location, and the H3F3A mutant cases tended to be younger on 
average. Histopathology in this group was oligoastrocytoma (two 
cases), astrocytoma (two cases), oligodendroglioma (one case), 
and glioblastoma (two cases). All H3F3A mutations identified in 
this study involved the K27M amino acid substitution. No H3F3A 
G34 mutation or HIST1H3B mutations were detected.  H3F3A 
mutations at G34 are typically found in the cerebral hemispheres 
and occur in adolescence and in young adults, in contrast with 
H3F3A mutations at K27, which are most common in brainstem 
gliomas of young children, but may also occur in adults as shown 
by this study (9, 29).
The frequency of MGMT promoter methylation in adult 
brainstem glioma has not been adequately evaluated, although 
positive MGMT expression (correlating with an unmethylated 
MGMT promoter) was found in 64.7% of cases in one series (31). 
1p/19q codeletion is rarely detected in adult brainstem glioma. 
A genomic profiling study of nine adult brainstem gliomas identi-
fied one BRAF V600E mutation and two PIK3CA mutations (5). 
Mutations in AVCR1 (encoding a type I activin A receptor kinase) 
are commonly seen in pediatric DIPG and may lead to overacti-
vation of the BMP–TGF-β signaling pathway (32, 33). However, 
the frequency of AVCR1 mutations in adult brainstem glioma is 
unknown. Amplification of MYCN was found to define a subset 
of pediatric DIPG in one genomic analysis; the frequency of this 
finding in adult brainstem glioma is also unknown (34).
FUTURe DiReCTiOnS
Brainstem gliomas, particularly in adults, are not one disease. 
Armed with genomic sequencing technology that is becoming 
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increasingly sophisticated and widely available, the future of 
treatment for adult brainstem glioma lies in parsing out which 
tumors are most likely to respond to which therapies. Based 
on current knowledge, for example, it appears that most adult 
brainstem gliomas can be stratified into one of two groups based 
upon whether the tumor has an IDH mutation or H3F3A muta-
tion. Interestingly, IDH mutations lead to DNA hypermethyla-
tion throughout the genome, while H3F3A mutant tumors are 
associated with DNA hypomethylation (30, 35). So while both 
of these tumor types have a significant epigenetic basis, opposite 
strategies will be required to target the DNA methylation status 
of these two groups. Pharmacologic inhibition of histone H3 
demethylation has shown promise in preclinical studies on 
H3F3A-mutant brainstem glioma cell lines, and small molecule 
H3 demethylase inhibitors are in development (36, 37). The 
multihistone deacetylase inhibitor panobinostat has also been 
shown to restore methylation and normalize gene expression 
in preclinical models of DIPG (38). Other studies suggest that 
somatic histone H3 alterations may result an increased expres-
sion of bromodomain-containing protein 1 and 4 (BRD1 and 
BRD4) (37). Tumors with these mutations may thus be sus-
ceptible to treatment with a bromodomain inhibitor, several of 
which are in development. The subset of brainstem gliomas with 
MYCN amplification may also be susceptible to bromodomain 
inhibition (39).
Brainstem gliomas that harbor IDH mutations, on the other 
hand, may respond to hypomethylating agents, such as 5-azacy-
tidine and decitabine, both FDA approved for myelodysplastic 
syndrome. Though not yet confirmed by clinical trials, at least 
three preclinical studies have demonstrated a therapeutic effect of 
DNA hypomethylating agents on IDH1-mutant tumor cell lines 
(40–42). In one of these studies, 5-azacytidine was administered 
intraperitoneally to nude mice bearing subcutaneous xenografts 
derived from an IDH1-mutant anaplastic astrocytoma specimen. 
At week 14, tumor regression was observed in the 5-azacytidine-
treated mice, in stark contrast with the control mice (41). A recent 
study outlined a novel mechanism involved in the pathogenesis 
of IDH-mutant gliomas: methylation of insulator protein binding 
sites within DNA, leading to aberrant contact of the PDGFRA 
promoter with distant enhancer elements, causing overexpression 
of PDGFRA, a known glioma oncogene (42). In vitro treatment of 
IDH1-mutant BT142 gliomaspheres with 5-azacytidine reduced 
methylation of the insulator protein binding site by ~2.5-fold and 
downregulated PDGFRA expression 5-fold. Phase I pharmacoki-
netic/pharmacodynamic trials would be needed to confirm the 
ability of DNA hypomethylating drugs such as 5-azacytidine and 
decitabine to reach tumors within the central nervous system at 
therapeutic concentrations.
A phase I trial of AG-120, an oral inhibitor of mutant IDH1, 
demonstrated stable disease in 10 of 20 patients with IDH1-
mutant glioma, with a 6-month clinical benefit response rate 
of 25%. Further testing is ongoing. Other mutations that have 
been reported in adult brainstem glioma, such as mutations in 
PDGFRA, PIK3CA, and PPM1D, are also potentially targetable 
with drugs that are either already commercially available or in 
development.
Incorporating genomic data into a strategy for treatment – an 
approach called “precision medicine” by some  –  also faces 
significant challenges. For this strategy to get off the ground, 
obtaining tumor tissue for genomic analysis is a prerequisite. 
While operating on the brainstem requires great expertise and 
care, the precision with which a neurosurgeon can operate these 
days, coupled with decreasing tissue requirements for genomic 
analysis, makes obtaining tissue on a standard basis a much more 
reasonable option now.
Another challenge in adopting a precision medicine approach 
is figuring out how to incorporate such a strategy into the tradi-
tional clinical trial framework. Adopting such methodology, a 
clinical trial for pediatric patients with DIPG – still ongoing, but 
not recruiting – uses the result of EGFR and MGMT promoter 
methylation testing to determine whether patients receive 
temozolomide and/or erlotinib in addition to bevacizumab 
and irradiation (NCT01182350). Unfortunately, the incidence 
of adult brainstem glioma is likely too low for anything larger 
than a small-scale trial to be performed. However, adults with 
brainstem glioma may still be candidates for clinical trials as 
participants in so-called “basket” trials that stratify patients 
by molecular alteration regardless of tumor histology. For 
example, adults with recurrent brainstem glioma harboring a 
BRAF V600E mutation may qualify for the recently initiated 
NCI-MATCH study, which includes an arm for patients with 
tumors with BRAF V600E mutation to receive a combination 
of dabrafenib and trametinib. Patients may also seek to have 
genomic profiling performed on their tumor tissue outside the 
framework of a clinical trial. In these instances, patients must 
understand that using such data to dictate management is an as-
of-yet unproven treatment strategy, promising though it may be.
Immunotherapy may also one day play a role in the treat-
ment of brainstem glioma in adults. Vaccine trials for adult 
malignant glioma have been conducted for over a decade, but 
until recently, these trials usually required patients to undergo 
gross-total or near-gross total resection, which precluded patients 
with brainstem glioma from participating. Recently, however, 
some vaccine trials have begun allowing patients with significant 
residual disease to participate. Vaccines that are manufactured 
using autologous tumor lysate often require more tissue than is 
available for patients with brainstem glioma. However, trials that 
utilize tumor-associated peptides usually have much less restric-
tive tissue requirements.
Immune checkpoint inhibitors that block targets such as PD1, 
PDL1, and CTLA4 have recently shown impressive activity across 
a range of advanced malignancies. These therapies have not yet 
been evaluated for brainstem glioma, though interest is high.
COnCLUSiOn
Because adult brainstem glioma is a collection of clinical and 
histological entities, individual patient treatment depends 
on symptoms, performance status, age, histology, molecular 
pathology, and availability of new therapeutic studies. IDH 
and histone mutations are relatively recent discoveries and are 
only now being introduced into upcoming pediatric studies; 
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retrospective analyses are underway in selected adult patient 
populations. Given the rapid advances in the field in molecular 
classification, epigenetics and cancer therapeutics, it is likely 
that we will make significant gains in this vein over the next dec-
ade, thereby enabling evidence-based management algorithms 
for both pediatric and adult DIPG as well as the larger group 
of brainstem tumors. For now, we judiciously biopsy/resect 
patients whom we deem safe to do so for the purpose of sympto-
matic control and molecular testing for prognosis as well as for 
enrolling into therapeutic studies which usually require tissue 
diagnosis and mutation status (e.g., IDH1/2 mutation, BRAF 
mutation, Histone 3 mutation). Radiation and temozolomide 
are used routinely upfront and re-radiation is often offered at 
recurrence. We still have much to learn about the pathogenesis 
of adult brainstem glioma, but landmark studies on pediatric 
DIPG on one side and adult non-brainstem glioma on the 
other is likely to have a considerable degree of relevance. As 
our understanding of adult brainstem glioma increases, better 
treatments are sure to follow.
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